Drugs / Azficel-T (autologous fibroblasts)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02120781 | Mar 2014 → Apr 2016 | dystonia-aphonia syndrome, voice disorders | Castle Creek Biosciences, LLC. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azficel-T (autologous fibroblasts) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02120781 ↗ |
| Modality | Cell therapy | “autologous cultured fibroblasts (azficel-T, n=14)” NCT02120781 ↗ |
| Route | Other | “will be injected transorally or percutaneously” NCT02120781 ↗ |